<document>
<type>497K
<sequence>1
<filename>d822541d497k.htm
<description>FORM 497K
<text>
<html><head>
<title>Form 497K</title>
</head>
<body>
<div> <div><a name="xx_67079697-befb-4ee2-965a-264bcf8cecc3_1"></a> <div> <div> </div>
<div> <div><font> </font></div>
<div>
<table>
<tr>
<td> <div> <div>
<img alt=" " src="g822541ishares2019sm.jpg"/></div>
<div><font> </font></div> </div> </td>
<td> <div> <div><font>August 1, 2024</font></div> </div> </td> </tr>
<tr>
<td> <div> <div><font> </font></div> </div> </td>
<td> <div>
<div><font> </font></div> </div> </td> </tr> </table> </div>
<div><font> </font></div> <div>
<table>
<tr>
<td> <div> <div>
<img alt=" " src="g822541imgd444c35c1.jpg"/></div> <div><font> </font></div> </div>
</td>
<td> <div> <div><font>2024 Summary Prospectus</font></div> </div> </td> </tr> </table> </div> <div>
<div><font>• </font><font>iShares U.S. Pharmaceuticals ETF</font><font> | </font><font>IHE</font><font> | </font><font>NYSE ARCA</font></div> </div> <div> <div><font>Before you invest, you may want to review the Fund’s prospectus, which contains more
</font><font>information about the Fund and its risks. You can find the Fund’s prospectus (including </font><font>amendments and supplements) and other information about the Fund, including the
</font><font>Fund’s statement of additional information and shareholder reports, online at https://www.blackrock.com/prospectus.</font><font> You can also get this information at no cost by calling </font><font>1-800-iShares (1-800-474-2737) or
by sending an e-mail request to </font><font>iSharesETFs@blackrock.com, or from your financial professional. The Fund’s prospectus </font><font>and statement of additional information, both dated August 1, 2024, as amended and
</font><font>supplemented from time to time, are incorporated by reference into (legally made a part </font><font>of) this Summary Prospectus. Information on the Fund’s net asset value, market price,
</font><font>premiums and discounts, and bid-ask spreads can be found at
</font><font>https://www.iShares.com</font><font>.</font></div> </div>
<div>
<br/><font> </font><font> </font></div>
<div> <div><font> </font></div> </div>
<div> <div><font> </font></div> </div>
<div> <div><font>The Securities and Exchange Commission has not approved or disapproved these </font><font>securities or passed upon the adequacy of this prospectus. Any representation to the </font><font>contrary is a criminal
offense.</font></div> </div> </div> </div> </div> <div> </div> <hr/> </div>
<p> </p>
<hr size="3"/>
<div> <div><a name="xx_77ff9158-af04-4dea-afbb-c2aac2fbf8a0_1"></a> <div> <div> </div>
<div> <div><font>iSHARES</font><font>®</font><font> U.S. PHARMACEUTICALS ETF</font></div>
<div> <div><font>Ticker: IHE</font><font>Stock Exchange: NYSE Arca </font></div> </div> <div> <div><font>Investment Objective</font></div> </div> <div> <div><font>The iShares U.S. Pharmaceuticals ETF (the
</font><font>“</font><font>Fund</font><font>”</font><font>) seeks to track the investment </font><font>results of an index composed of U.S. equities in the pharmaceuticals
sector.</font></div> </div> <div> <div><font>Fees and Expenses</font></div> </div>
<div> <div><font>The following table describes the fees and expenses that you will incur if you buy, hold
</font><font>and sell shares of the Fund. The investment advisory agreement between iShares Trust </font><font>(the </font><font>“</font><font>Trust</font><font>”</font><font>) and BlackRock Fund Advisors (</font><font>“</font><font>BFA</font><font>”</font><font>) (the </font><font>“</font><font>Investment Advisory </font><font>Agreement</font><font>”</font><font>) provides that BFA will pay all operating expenses of the Fund, except: (i) </font><font>the management fees, (ii) interest
expenses, (iii) taxes, (iv) expenses incurred with </font><font>respect to the acquisition and disposition of portfolio securities and the execution of </font><font>portfolio transactions, including brokerage commissions, (v) distribution fees or </font><font>expenses, and (vi) litigation expenses
and any extraordinary expenses.</font></div> </div> <div> <div><font>You may pay other
fees, such as brokerage commissions and other fees to </font><font>financial intermediaries, which are not reflected in the tables and examples </font><font>below.</font></div> </div> <div><font> </font></div>
<div> <div> </div> </div> <div>
<table>
<tr>
<td colspan="4"> <div>
<div> <div><font>Annual Fund
Operating Expenses</font><font> </font></div> <div><font>(ongoing expenses that you pay each year as a</font><font> </font></div>
<div><font>percentage of the value of your investments)</font><font>1</font> <div> </div> </div> </div> </div> </td> </tr>
<tr>
<td> <div>
<div>
<div><font>Management</font><font>
</font></div> <div><font>Fees</font></div> </div> </div> </td>
<td> <div>
<div>
<div><font>Distribution</font></div> <div><font>and Service</font></div> <div><font>(12b-1)
Fees</font></div> </div> </div> </td>
<td> <div>
<div>
<div><font>Other</font><font>
</font></div> <div><font>Expenses</font><font>2</font> <div> </div> </div> </div> </div> </td>
<td> <div>
<div> <div><font>Total
Annual</font><font> </font></div> <div><font>Fund</font><font> </font></div>
<div><font>Operating</font><font>
</font></div> <div><font>Expenses</font></div> </div> </div> </td> </tr>
<tr>
<td> <div> <div><font>0.39%</font></div> </div> </td>
<td> <div>
<div> <div><font>None</font></div> </div> </div> </td>
<td> <div>
<div> <div><font>0.00%</font></div> </div> </div> </td>
<td> <div>
<div> <div><font>0.39%</font></div> </div> </div> </td> </tr> </table> </div>
<div> <hr/> </div> <div>
<div> <div><font>1</font></div>
<div><font>Operating expenses paid by BFA under the Investment Advisory Agreement exclude </font><font>acquired fund fees and expenses, if any.</font></div> </div> <div> </div> </div> <div> <div>
<div><font>2</font></div>
<div><font>The amount rounded to 0.00%.</font></div> </div> <div>
</div> </div> <div> <div><font>Example. </font><font>This Example is intended to help you compare the cost of owning shares of </font><font>the Fund with the cost of investing in other
funds. The Example assumes that you </font><font>invest $10,000 in the Fund for the time periods indicated and then sell all of your </font><font>shares at the end of those periods. The Example also assumes that your investment </font><font>has a 5% return each year and that the
Fund’s operating expenses remain the same. </font><font>Although your actual costs may be higher or lower, based on these assumptions, your </font><font>costs would be:</font></div> </div> <div><font> </font></div>
<div> <div> </div> </div> <div>
<table>
<tr>
<td> <div>
<div> <div><font>1
Year</font></div> </div> </div> </td>
<td> <div>
<div> <div><font>3
Years</font></div> </div> </div> </td>
<td> <div>
<div> <div><font>5
Years</font></div> </div> </div> </td>
<td> <div> <div>
<div><font>10 Years</font></div> </div> </div> </td> </tr>
<tr>
<td> <div>
<div>
<div><font>$</font><font>40</font></div> </div> </div> </td>
<td> <div>
<div>
<div><font>$</font><font>125</font></div> </div> </div> </td>
<td> <div>
<div>
<div><font>$</font><font>219</font></div> </div> </div> </td>
<td> <div>
<div>
<div><font>$</font><font>493</font></div> </div> </div> </td> </tr> </table>
</div> <div> </div> </div> <div> </div> <div>
<div> <div> <div><font>S-1</font></div> </div> </div> </div>
</div> </div> <div> </div> <hr/> </div>
<p> </p>
<hr size="3"/>
<div> <div><a name="xx_77ff9158-af04-4dea-afbb-c2aac2fbf8a0_2"></a> <div> <div> </div>
<div> <div><font>Portfolio Turnover.</font><font> The Fund may pay </font><font>transaction costs, such as commissions, </font><font>when it buys and sells securities (or
</font><font>“</font><font>turns over</font><font>”</font><font> its portfolio). A higher </font><font>portfolio turnover rate may indicate </font><font>higher transaction costs and may result </font><font>in higher taxes when Fund shares are </font><font>held in a taxable account. These costs, </font><font>which are not reflected in the Annual </font><font>Fund Operating Expenses or in the </font><font>Example, affect the Fund’s </font><font>performance. During the most recent </font><font>fiscal year, the Fund's portfolio turnover </font><font>rate was 42% of the average value of its </font><font>portfolio.</font></div>
<div> <div><font>Principal Investment </font><font>Strategies</font></div> </div> <div> <div><font>The Fund seeks to track the investment </font><font>results of the Dow Jones U.S. Select </font><font>Pharmaceuticals Index (the </font><font>“</font><font>Underlying
</font><font>Index</font><font>”</font><font>), which measures the
</font><font>performance of the pharmaceuticals </font><font>sector of the U.S. equity market, as </font><font>defined by S&amp;P Dow Jones Indices LLC </font><font>(the
</font><font>“</font><font>Index Provider</font><font>”</font><font> or </font><font>“</font><font>SPDJI</font><font>”</font><font>). The </font><font>Underlying Index includes </font><font>pharmaceutical companies such as </font><font>manufacturers of prescription or over-the-counter</font><font> drugs or vaccines. The </font><font>Underlying Index may include large-, </font><font>mid- or small-capitalization companies. </font><font>As of March 31, 2024, a significant </font><font>portion of the Underlying Index is </font><font>represented by securities of companies </font><font>in the healthcare and pharmaceuticals </font><font>industries or sectors. The components </font><font>of the Underlying Index are likely to </font><font>change over time.</font></div> </div>
<div> <div><font>BFA uses an indexing approach to try to </font><font>achieve the Fund’s investment </font><font>objective. Unlike many investment </font><font>companies, the Fund does not try to
</font><font>“</font><font>beat</font><font>”</font><font> the index it tracks and does not </font><font>seek temporary defensive positions </font></div> </div> </div>
<div> <div><font>when markets decline or appear </font><font>overvalued.</font></div> <div>
<div><font>Indexing may eliminate the chance that </font><font>the Fund will substantially outperform </font><font>the Underlying Index but also may </font><font>reduce some of the risks of active </font><font>management, such as poor security </font><font>selection. Indexing seeks to achieve </font><font>lower costs and better after-tax </font><font>performance by aiming to keep portfolio </font><font>turnover low in comparison to actively </font><font>managed investment companies.</font></div> </div>
<div> <div><font>BFA uses a representative sampling </font><font>indexing strategy to manage the Fund.
</font><font>“</font><font>Representative
sampling</font><font>”</font><font> is an </font><font>indexing
strategy that involves investing </font><font>in a representative sample of securities </font><font>that collectively has an
investment </font><font>profile similar to that of an applicable </font><font>underlying index. The securities </font><font>selected are expected to have, in the </font><font>aggregate, investment characteristics </font><font>(based on factors such as market </font><font>capitalization and industry weightings), </font><font>fundamental characteristics (such as </font><font>return variability and yield) and liquidity </font><font>measures similar to those of an </font><font>applicable underlying index. The Fund </font><font>may or may not hold all of the securities </font><font>in the Underlying Index.</font></div> </div>
<div> <div><font>The Fund generally will invest at least </font><font>80% of its assets in the component </font><font>securities of its Underlying Index and </font><font>may invest up to 20% of its assets in </font><font>certain futures, options and swap </font><font>contracts, cash and cash equivalents, </font><font>including shares of money market funds </font><font>advised by BFA or its affiliates, as well </font><font>as in securities not included in the </font><font>Underlying Index, but which BFA </font><font>believes will help the Fund track the </font><font>Underlying Index. Cash and cash </font><font>equivalent investments associated with </font><font>a derivative position will be treated as </font><font>part of that position for the purposes of </font></div> </div> </div>
<div> </div> <div> <div> <div> <div><font>S-2</font></div> </div> </div> </div> </div> </div> <div> </div>
<hr/> </div>
<p> </p>
<hr size="3"/>
<div> <div><a name="xx_77ff9158-af04-4dea-afbb-c2aac2fbf8a0_3"></a> <div> <div> </div>
<div> <div><font>calculating the percentage of </font><font>investments included in the Underlying </font><font>Index. The Fund seeks to track the </font><font>investment results of the Underlying </font><font>Index before fees and expenses of the </font><font>Fund.</font></div> <div> <div><font>The Fund may
lend securities </font><font>representing up to one-third of the value </font><font>of the Fund's total assets (including the </font><font>value of any collateral received).</font></div> </div> <div> <div><font>The Underlying Index is sponsored by </font><font>SPDJI, which is</font><font> </font><font>independent of the Fund
</font><font>and BFA. The Index Provider determines </font><font>the composition and relative weightings </font><font>of the securities in the Underlying Index </font><font>and publishes information regarding the </font><font>market value of the Underlying Index.</font></div> </div> <div> <div><font>Industry Concentration Policy.</font><font> The
</font><font>Fund will concentrate its investments </font><font>(</font><font>i.e.</font><font>, hold 25% or more of its total </font><font>assets) in a particular industry or group </font><font>of industries to approximately the same </font><font>extent that the Underlying Index is </font><font>concentrated. For purposes of this </font><font>limitation, securities of the U.S. </font><font>government (including its agencies and </font><font>instrumentalities) and repurchase </font><font>agreements collateralized by U.S. </font><font>government securities are not </font><font>considered to be issued by members of </font><font>any industry.</font></div> </div> <div> <div><font>Summary of Principal Risks</font></div> </div> <div> <div><font>As with any investment, you could lose </font><font>all or part of your investment in the </font><font>Fund, and the Fund's performance could </font><font>trail that of other investments. The Fund </font><font>is subject to certain risks, including the </font><font>principal risks noted below, any of </font><font>which may adversely affect the Fund's </font><font>net asset value per share (</font><font>“</font><font>NAV</font><font>”</font><font>), </font><font>trading price, yield, total return and </font><font>ability
to meet its investment objective. </font><font>Certain key risks are prioritized below </font><font>(with others following in
alphabetical </font></div> </div> </div> <div>
<div><font>order), but the relative significance of </font><font>any risk is difficult
to predict and may </font><font>change over time. You should review </font><font>each risk factor carefully.</font></div>
<div> <div><font>Risk of Investing in the U.S</font><font>.</font><font> Investing </font><font>in U.S. issuers
subjects the Fund to </font><font>legal, regulatory, political, currency, </font><font>security, and economic risks that are </font><font>specific to the U.S. Certain changes in </font><font>the U.S., such as a weakening of the </font><font>U.S. economy or a decline in its </font><font>financial markets, may have an adverse </font><font>effect on U.S. issuers.</font></div> </div> <div> <div><font>Pharmaceuticals Industry Risk.</font><font> </font><font>Companies in the pharmaceuticals </font><font>industry may be affected by industry </font><font>competition, dependency on a limited </font><font>number of products, obsolescence of </font><font>products, government approvals and </font><font>regulations, loss or impairment of </font><font>intellectual property rights and litigation </font><font>regarding product liability.</font></div> </div>
<div> <div><font>Healthcare Sector Risk</font><font>.</font><font> The </font><font>profitability of companies
in the </font><font>healthcare sector may be affected by </font><font>government regulations and </font><font>government healthcare programs, </font><font>increases or decreases in the cost of </font><font>medical products and services, an </font><font>increased emphasis on outpatient </font><font>services, demand for medical products </font><font>and services and product liability </font><font>claims, among other factors. Many </font><font>healthcare companies are heavily </font><font>dependent on patent protection, and </font><font>the expiration of a company’s patent </font><font>may adversely affect that company’s </font><font>profitability. Healthcare companies are </font><font>subject to competitive forces that may </font><font>result in price discounting, and may be </font><font>thinly capitalized and susceptible to </font><font>product obsolescence.</font></div> </div>
<div> <div><font>Equity Securities Risk</font><font>.</font><font> Equity </font><font>securities are subject
to changes in </font><font>value, and their values may be more </font></div> </div> </div> <div> </div>
<div> <div> <div> <div><font>S-3</font></div> </div> </div> </div> </div> </div> <div> </div>
<hr/> </div>
<p> </p>
<hr size="3"/>
<div> <div><a name="xx_77ff9158-af04-4dea-afbb-c2aac2fbf8a0_4"></a> <div> <div> </div>
<div> <div><font>volatile than those of other asset </font><font>classes. The value of a security may </font><font>decline for a number of reasons that </font><font>may directly relate to the issuer as well </font><font>as due to general industry or market </font><font>conditions. Common stock is </font><font>subordinated to preferred securities and </font><font>debt in a company’s capital structure. </font><font>Common stock has the lowest priority, </font><font>and the greatest risk, with respect to </font><font>dividends and any liquidation payments </font><font>in the event of an issuer’s bankruptcy.</font></div> <div> <div><font>Market Risk</font><font>.</font><font> The Fund could lose </font><font>money over short periods due to short-term</font><font> market movements and over </font><font>longer periods during more prolonged </font><font>market downturns. Local, regional or </font><font>global events such as war, acts of </font><font>terrorism, pandemics or other public </font><font>health issues, recessions, the prospect </font><font>or occurrence of a sovereign default or </font><font>other financial crisis, or other events </font><font>could have a significant impact on the </font><font>Fund and its investments and could </font><font>result in increased premiums or </font><font>discounts to the Fund’s NAV.</font></div> </div>
<div> <div><font>Index-Related Risk. </font><font>The Index Provider </font><font>may rely on various sources of
</font><font>information to assess the criteria of </font><font>components of the Underlying Index, </font><font>including information that may be based </font><font>on assumptions and estimates. Neither </font><font>the Fund nor BFA can offer assurances </font><font>that the Index Provider’s methodology </font><font>or sources of information will provide an </font><font>accurate assessment of included </font><font>components. Errors in index data, index </font><font>computations or the construction of the </font><font>Underlying Index in accordance with its </font><font>methodology may occur, and the Index </font><font>Provider may not identify or correct </font><font>them promptly or at all, which may have </font><font>an adverse impact on the Fund and its </font><font>shareholders. Unusual market </font><font>conditions or other unforeseen </font><font>circumstances (such as natural </font></div> </div> </div>
<div> <div><font>disasters, political unrest or war) may
</font><font>impact the Index Provider or a third-party</font><font> data provider and could cause the </font><font>Index Provider to postpone a scheduled </font><font>rebalance. This could cause the </font><font>Underlying Index to vary from its normal </font><font>or expected composition.</font></div>
<div> <div><font>Asset Class Risk.</font><font> The securities and </font><font>other assets in the Underlying Index or </font><font>in the Fund’s portfolio may </font><font>underperform in comparison to financial </font><font>markets generally, a particular financial </font><font>market, another index, or other asset </font><font>classes.</font></div> </div> <div> <div><font>Authorized Participant Concentration </font><font>Risk.</font><font> An </font><font>“</font><font>Authorized Participant</font><font>”</font><font> is a </font><font>member or participant of a clearing
</font><font>agency registered with the SEC, which </font><font>has a written agreement with the Fund </font><font>or one of its service providers that </font><font>allows the Authorized Participant to </font><font>place orders for the purchase and </font><font>redemption of creation units (</font><font>“</font><font>Creation </font><font>Units</font><font>”</font><font>). Only an Authorized Participant </font><font>may
engage in creation or redemption </font><font>transactions directly with the Fund. </font><font>There are a limited number of </font><font>institutions that may act as Authorized </font><font>Participants for the Fund, including on </font><font>an agency basis on behalf of other </font><font>market participants. No Authorized </font><font>Participant is obligated to engage in </font><font>creation or redemption transactions. To </font><font>the extent that Authorized Participants </font><font>exit the business or do not place </font><font>creation or redemption orders for the </font><font>Fund and no other Authorized </font><font>Participant places orders, Fund shares </font><font>are more likely to trade at a premium or </font><font>discount to NAV and possibly face </font><font>trading halts or delisting.</font></div> </div>
<div> <div><font>Concentration Risk.</font><font> The Fund may be </font><font>susceptible to an increased risk of loss, </font><font>including losses due to adverse events </font><font>that affect the Fund’s investments more </font></div> </div> </div>
<div> </div> <div> <div> <div> <div><font>S-4</font></div> </div> </div> </div> </div> </div> <div> </div>
<hr/> </div>
<p> </p>
<hr size="3"/>
<div> <div><a name="xx_77ff9158-af04-4dea-afbb-c2aac2fbf8a0_5"></a> <div> <div> </div>
<div> <div><font>than the market as a whole, to the </font><font>extent that the Fund’s investments are </font><font>concentrated in the securities or other </font><font>assets of one or more issuers, countries </font><font>or other geographic units, markets, </font><font>industries, project types, or asset </font><font>classes.</font></div>
<div> <div><font>Cybersecurity Risk</font><font>.</font><font> Failures or </font><font>breaches of the
electronic systems of </font><font>the Fund, its adviser, distributor,</font><font> </font><font>Index </font><font>Provider, other service providers,
</font><font>counterparties, or issuers of assets in </font><font>which the Fund invests may cause </font><font>disruptions that negatively impact the </font><font>Fund and its shareholders. While the </font><font>Fund has established business </font><font>continuity plans and risk management </font><font>systems seeking to address system </font><font>breaches or failures, there are inherent </font><font>limitations in such plans and systems. </font><font>The Fund cannot control the </font><font>cybersecurity plans and systems of its </font><font>service providers, counterparties, and </font><font>other third parties whose activities </font><font>affect the Fund.</font></div> </div>
<div> <div><font>Issuer Risk</font><font>.</font><font> The performance of the </font><font>Fund
depends on the performance of </font><font>individual securities or other assets to </font><font>which the Fund has exposure. The
value </font><font>of securities or other assets may </font><font>decline, or perform differently from the </font><font>market as a whole, due to changes in </font><font>the financial condition or credit rating of </font><font>the issuer or counterparty.</font></div> </div> <div> <div><font>Large-Capitalization Companies Risk.</font><font> </font><font>Large-capitalization companies may be </font><font>less able than smaller-capitalization </font><font>companies to adapt to changing market </font><font>conditions and competitive challenges. </font><font>Large-capitalization companies may be </font><font>more mature and subject to more </font><font>limited growth potential compared with </font><font>smaller-capitalization companies. The </font><font>performance of large-capitalization </font><font>companies could trail the overall </font></div> </div> </div>
<div> <div><font>performance of the broader securities
</font><font>markets.</font></div> <div> <div><font>Management Risk</font><font>.</font><font> The Fund is not </font><font>actively managed, and BFA generally </font><font>does not attempt to take defensive </font><font>positions under any market conditions, </font><font>including declining markets. As the Fund </font><font>will not fully replicate the Underlying </font><font>Index and may hold securities or other </font><font>assets not included in the Underlying </font><font>Index, it is subject to the risk that the </font><font>investment strategy of BFA may not </font><font>produce the intended results. There is </font><font>no guarantee that the Fund’s investment </font><font>results will have a high degree of </font><font>correlation to those of the Underlying </font><font>Index or that the Fund will achieve its </font><font>investment objective.</font></div> </div>
<div> <div><font>Market Trading Risk</font><font>.</font><font> The Fund faces </font><font>numerous market
trading risks, </font><font>including the potential lack of an active </font><font>market for Fund shares (including </font><font>through a trading halt), losses from </font><font>trading in secondary markets, periods of </font><font>high volatility, and disruptions in the </font><font>process of creating and redeeming Fund </font><font>shares. Any of these factors, among </font><font>others, may lead to the Fund’s shares </font><font>trading in the secondary market at a </font><font>premium or discount to NAV or to the </font><font>intraday value of the Fund’s portfolio </font><font>holdings. If you buy Fund shares at a </font><font>time when the market price is at a </font><font>premium to NAV or sell Fund shares at a </font><font>time when the market price is at a </font><font>discount to NAV, you may pay </font><font>significantly more or receive </font><font>significantly less than the underlying </font><font>value of the Fund shares.</font></div> </div> <div> <div><font>Non-Diversification Risk</font><font>.</font><font> The Fund is </font><font>classified as </font><font>“</font><font>non-diversified.</font><font>”</font><font> This </font><font>means that, compared with funds that </font><font>are classified as </font><font>“</font><font>diversified,</font><font>”</font><font> the Fund </font><font>may invest a greater percentage of its
</font><font>assets in securities or other instruments </font></div> </div> </div> <div> </div>
<div> <div> <div> <div><font>S-5</font></div> </div> </div> </div> </div> </div> <div> </div>
<hr/> </div>
<p> </p>
<hr size="3"/>
<div> <div><a name="xx_77ff9158-af04-4dea-afbb-c2aac2fbf8a0_6"></a> <div> <div> </div>
<div> <div><font>representing a small number of issuers
</font><font>or counterparties and thus may be more </font><font>susceptible to the risks associated with </font><font>these particular issuers or </font><font>counterparties. As a result, the Fund's </font><font>performance may depend to a greater </font><font>extent on the performance of a small </font><font>number of issuers or counterparties, </font><font>which may lead to more volatility in the </font><font>Fund’s NAV.</font></div> <div> <div><font>Operational Risk</font><font>.</font><font> The Fund is exposed </font><font>to operational risks arising from a </font><font>number of factors, including, but not </font><font>limited to, human error, processing and </font><font>communication errors, errors of the </font><font>Fund’s service providers, counterparties </font><font>or other third parties, failed or </font><font>inadequate processes and technology </font><font>or systems failures. The Fund and BFA </font><font>seek to reduce these operational risks </font><font>through controls and procedures. </font><font>However, these measures do not </font><font>address every possible risk and may be </font><font>inadequate to address significant </font><font>operational risks.</font></div> </div> <div> <div><font>Securities Lending Risk. </font><font>The Fund may </font><font>engage in securities lending. Securities </font><font>lending involves the risk that the Fund </font><font>may lose money because the borrower </font><font>of the loaned securities fails to return </font><font>the securities in a timely manner or at </font><font>all. The Fund could also lose money in </font><font>the event of a decline in the value of </font><font>collateral provided for loaned securities </font><font>or a decline in the value of any </font></div> </div> </div> <div>
<div><font>investments made with cash collateral. </font><font>These events could also
trigger adverse </font><font>tax consequences for the Fund.</font></div> <div> <div><font>Tracking Error Risk</font><font>.</font><font> The Fund may be </font><font>subject to </font><font>“</font><font>tracking error,</font><font>”</font><font> which is the </font><font>divergence of the Fund’s performance </font><font>from that of the Underlying Index. </font><font>Tracking error may occur because of </font><font>differences between the securities and </font><font>other instruments held in the Fund’s </font><font>portfolio and those included in the </font><font>Underlying Index, pricing differences, </font><font>transaction costs incurred by the Fund, </font><font>the Fund’s holding of uninvested cash, </font><font>differences in timing of the accrual or </font><font>the valuation of dividends or interest </font><font>received by the Fund or distributions </font><font>paid to the Fund’s shareholders, the </font><font>requirements to maintain pass-through </font><font>tax treatment, portfolio transactions </font><font>carried out to minimize the distribution </font><font>of capital gains to shareholders, </font><font>acceptance of custom baskets, changes </font><font>to the Underlying Index or the costs to </font><font>the Fund of complying with various new </font><font>or existing regulatory requirements, </font><font>among other reasons. This risk may be </font><font>heightened during times of increased </font><font>market volatility or other unusual </font><font>market conditions. Tracking error also </font><font>may result because the Fund incurs fees </font><font>and expenses, while the Underlying </font><font>Index does not.</font></div> </div> <div>
</div> </div> <div> </div> <div> <div> <div>
<div><font>S-6</font></div> </div> </div> </div> </div> </div> <div> </div>
<hr/> </div>
<p> </p>
<hr size="3"/>
<div> <div><a name="xx_77ff9158-af04-4dea-afbb-c2aac2fbf8a0_7"></a> <div> <div> </div>
<div> <div><font>Performance
Information</font></div> <div> <div><font>The bar chart and table that follow show how the Fund has
performed on a calendar </font><font>year basis and provide some indication of the risks of investing in the Fund by showing </font><font>how the Fund’s average annual returns for 1, 5, and 10 years compare with the </font><font>Underlying Index. Both assume that
all dividends and distributions have been </font><font>reinvested in the Fund. Past performance (before and after taxes) does not necessarily </font><font>indicate how the Fund will perform in the future.</font></div> </div> <div> <div><font>Calendar Year-by-Year Returns</font><font>1</font><font> </font></div> </div> <div>
<img alt=" " src="g822541ihedy.jpg"/><font> </font></div>
<div> <hr/> </div> <div>
<div> <div><font>1</font></div>
<div><font>The Fund’s year-to-date return as of June 30, 2024 was 8.35%.</font></div> </div>
<div> </div> </div> <div> <div><font>The best calendar quarter return
during the periods shown above was 14.91% in the </font><font>4th quarter of 2019; the worst was -16.01% in the 4th quarter of 2018.</font></div> </div>
<div> <div><font>Updated performance information, including the Fund’s current NAV, may be obtained
</font><font>by visiting our website at www.iShares.com or by calling 1-800-iShares (1-800-474-2737)</font><font> (toll
free).</font></div> </div> <div> <div><font>Average Annual Total Returns</font> <br/><font>(for the periods ended December 31, 2023)</font><font> </font></div> </div>
<div> <div> </div> </div> <div>
<table>
<tr>
<td> <div> <div><font> </font></div> </div> </td>
<td> <div> <div><font>One Year</font></div> </div> </td>
<td> <div> <div><font>Five Years</font></div> </div> </td>
<td> <div> <div><font>Ten Years</font></div> </div> </td> </tr>
<tr>
<td> <div> <div><font>(Inception Date: 5/1/2006)</font></div> </div> </td>
<td> <div>
<div> <div> </div> </div> </div> </td>
<td> <div>
<div> <div> </div> </div> </div> </td>
<td> <div>
<div> <div> </div> </div> </div> </td> </tr>
<tr>
<td> <div> <div><font>Return Before Taxes</font></div> </div> </td>
<td> <div>
<div> <div><font>0.99%</font></div> </div> </div> </td>
<td> <div>
<div> <div><font>7.36%</font></div> </div> </div> </td>
<td> <div>
<div> <div><font>6.15%</font></div> </div> </div> </td> </tr>
<tr>
<td> <div> <div><font>Return After Taxes on Distributions</font><font>1</font>
<div> </div> </div> </div> </td>
<td> <div>
<div> <div><font>0.64%</font></div> </div> </div> </td>
<td> <div>
<div> <div><font>6.95%</font></div> </div> </div> </td>
<td> <div>
<div> <div><font>5.78%</font></div> </div> </div> </td> </tr>
<tr>
<td> <div> <div><font>Return After Taxes on Distributions and Sale of Fund </font></div> <div><font>Shares</font><font>1</font> <div> </div> </div>
</div> </td>
<td> <div>
<div> <div><font>0.81%</font></div> </div> </div> </td>
<td> <div>
<div> <div><font>5.74%</font></div> </div> </div> </td>
<td> <div>
<div> <div><font>4.90%</font></div> </div> </div> </td> </tr>
<tr>
<td> <div> <div><font>Dow Jones U.S. Select Pharmaceuticals Index</font><font> (Index </font></div>
<div><font>returns do not reflect deductions for fees, expenses, or </font></div>
<div><font>taxes)</font></div> </div> </td>
<td> <div>
<div> <div><font>1.25%</font></div> </div> </div> </td>
<td> <div>
<div> <div><font>7.68%</font></div> </div> </div> </td>
<td> <div>
<div> <div><font>6.42%</font></div> </div> </div> </td> </tr>
</table> </div> <div> <hr/> </div> <div>
<div> <div><font>1</font></div>
<div><font>After-tax returns in the table above are calculated using the historical highest individual
</font><font>U.S. federal marginal income tax rates and do not reflect the impact of state or local taxes. </font><font>Actual
after-tax returns depend on an investor’s tax situation and may differ from those </font><font>shown, and after-tax returns shown are not relevant to tax-exempt investors or investors
</font><font>who hold shares through tax-deferred arrangements, such as 401(k) plans or individual </font><font>retirement accounts
(</font><font>“</font><font>IRAs</font><font>”</font><font>). Fund returns after taxes on distributions and sales of Fund </font><font>shares are calculated assuming that an investor has
sufficient capital gains of the same </font><font>character from other investments to offset any capital losses from the sale of Fund shares. </font><font>As a result, Fund returns after taxes on distributions and sales of Fund shares may exceed </font><font>Fund returns before taxes
and/or returns after taxes on distributions.</font></div> </div> <div> </div> </div> </div> <div> </div> <div>
<div> <div> <div><font>S-7</font></div> </div> </div> </div>
</div> </div> <div> </div> <hr/> </div>
<p> </p>
<hr size="3"/>
<div> <div><a name="xx_77ff9158-af04-4dea-afbb-c2aac2fbf8a0_8"></a> <div> <div> </div>
<div> <div><font>Management</font></div>
<div> <div><font>Investment Adviser.</font><font> BlackRock Fund </font><font>Advisors.</font></div> </div> <div>
<div><font>Portfolio Managers.</font><font> Jennifer Hsui, </font><font>Greg Savage and Paul Whitehead (the
</font><font>“</font><font>Portfolio
Managers</font><font>”</font><font>) are primarily
</font><font>responsible for the day-to-day </font><font>management of the Fund. Each Portfolio </font><font>Manager supervises a portfolio </font><font>management team. Ms. Hsui, Mr. </font><font>Savage and Mr. Whitehead have been </font><font>Portfolio Managers of the Fund since </font><font>2012, 2008 and 2022, respectively.</font></div> </div> <div> <div><font>Purchase and Sale of Fund </font><font>Shares</font></div> </div>
<div> <div><font>The Fund is an exchange-traded fund </font><font>(commonly referred to as an </font><font>“</font><font>ETF</font><font>”</font><font>). </font><font>Individual shares of the Fund may only
</font><font>be bought and sold in the secondary </font><font>market through a broker-dealer. </font><font>Because ETF shares trade at market </font><font>prices rather than at NAV, shares may </font><font>trade at a price greater than NAV (a </font><font>premium) or less than NAV (a discount). </font><font>An investor may incur costs attributable </font><font>to the difference between the highest </font><font>price a buyer is willing to pay to </font><font>purchase shares of the Fund (bid) and </font><font>the lowest price a seller is willing to </font><font>accept for shares of the Fund (ask) </font><font>when buying or selling shares in the </font><font>secondary market (the </font><font>“</font><font>bid-ask </font><font>spread</font><font>”</font><font>).</font></div> </div> <div> </div> </div>
<div> <div><font>Tax
Information</font></div> <div> <div><font>The Fund intends to make distributions </font><font>that may be taxable to you as ordinary </font><font>income or capital gains, unless you are </font><font>investing through a tax-deferred </font><font>arrangement such as a 401(k) plan or </font><font>an IRA, in which case, your distributions </font><font>generally will be taxed when withdrawn.</font></div> </div>
<div> <div><font>Payments to Broker-Dealers </font><font>and Other Financial </font><font>Intermediaries</font></div> </div>
<div> <div><font>If you purchase shares of the Fund </font><font>through a broker-dealer or other </font><font>financial intermediary (such as a bank), </font><font>BFA or other related companies may </font><font>pay the intermediary for marketing </font><font>activities and presentations, educational </font><font>training programs, conferences, the </font><font>development of technology platforms </font><font>and reporting systems or other services </font><font>related to the sale or promotion of the </font><font>Fund. These payments may create a </font><font>conflict of interest by influencing the </font><font>broker-dealer or other intermediary and </font><font>your salesperson to recommend the </font><font>Fund over another investment. Ask your </font><font>salesperson or visit your financial </font><font>intermediary’s website for more </font><font>information.</font></div> </div> </div> <div> </div> <div>
<div> <div> <div><font>S-8</font></div> </div> </div> </div>
</div> </div> <div> </div> <hr/> </div>
<p> </p>
<hr size="3"/>
<div> <div><a name="xx_77ff9158-af04-4dea-afbb-c2aac2fbf8a0_9"></a> <div> <div> </div>
<div> <div><font> </font></div> </div>
<div> </div> <div> <div><font>[THIS PAGE INTENTIONALLY LEFT BLANK]</font></div> </div> </div> </div> <div> </div>
<hr/> </div>
<p> </p>
<hr size="3"/>
<div> <div><a name="xx_77ff9158-af04-4dea-afbb-c2aac2fbf8a0_10"></a> <div> <div> </div>
<div> <div><font> </font></div> </div>
<div> </div> <div> <div><font>[THIS PAGE INTENTIONALLY LEFT BLANK]</font></div> </div> </div> </div> <div> </div>
<hr/> </div>
<p> </p>
<hr size="3"/>
<div> <div><a name="xx_7f3951cf-0b69-454f-b2c8-58f45c47c5d6_1"></a> <div> <div> </div>
<div> <div><font>For more information visit www.iShares.com or
call 1-800-474-2737</font></div> </div> <div> </div> <div> <div><font>Investment Company Act file No.: 811-09729</font></div> </div> <div> </div>
<div>
<div><font>IS-SP-IHE-0824</font></div> </div> <div> </div>
<div> <div>
<img alt=" " src="g822541img588446782.jpg"/><font> </font></div> </div>
<div> <div>
<img alt=" " src="g822541br2015.jpg"/><font> </font></div> </div> </div> </div> <div>
</div> <hr/> </div></body></html>
</text>
</description></filename></sequence></type></document>
